As the CGT space grows, making therapies available to more patients will require an all-encompassing approach to improving efficiency to lower manufacturing costs. New seed train technologies can not only improve viral vector manufacturing but has applications for other types of adherent production ...
Patient-specific therapies come with unique logistics that bring added complexity and risk to supply chains. Manufacturing these therapies will continue to require robust supply chain management, stringent quality control and specialized components throughout the network — from facilities and ...
Much of the focus for making CGTs accessible and commercially viable has looked downstream at manufacturing, logistics, geography, centralization, and even intellectual property. However, the vast majority of ex vivo advanced therapies share the same starting point — blood — and the future of CGT ...
While it is still early days for CGTs in autoimmune disease, the field is actively pushing its own limits, working to translate scientific excitement into better, more accessible products. Not only could this lift cell therapies to new heights, but it could redefine them entirely.
The urgency of unmet need has not evaded the CGT sector, which has executed a ‘strategic pivot’ into autoimmune disease. Developers with B-cell targeting therapies originally designed to detect and kill cancer cells have recognized the potential of these assets to clear the autoreactive B cells that...
Advances have allowed for the creation of bispecific, ‘Fc-silenced,’ and other specialized antibody reagents tailored to specific research needs. These engineered antibodies are deepening our understanding of complex biological systems and accelerating research that informs the development of next-...
Wednesday, April 30, 2025
As the therapeutic potential of AAV gene therapy becomes increasingly evident, so does the demand for its widespread application; however, this surge in demand poses a formidable challenge in the need for increasingly scalable and efficient AAV production platforms. Leveraging recent advances in ...
An effective orchestration platform is now essential in optimizing processes, fostering collaboration, and ensuring the safe and effective administration of CGTs. These orchestration platforms are crucial tools for approved treatment center staff to navigate the complex processes involved in CGT ...
To scale up a process, there are several important considerations, starting with the selection of a target batch size. However, process scale-up can encounter challenges. Here, several key considerations will be discussed, and specific examples of potential challenges faced during the scale-up of ...
Wednesday, March 19, 2025
Immunotherapy has transformed the field of oncology by harnessing the immune system’s innate ability to mount targeted attacks on cancer cells. Building on this foundation, cell and gene therapies take immunotherapy to the next level by reprogramming genetic blueprints and engineering immune cells ...